Patent Law Weblog
recent posts
- Apple v. Squires: USPTO Director Has Unlimited Discretion on IPR Institution
- The Ghost in the Machine: Why GenAI Can Be Both a Brilliant Researcher and a Terrible Advocate
- Bayer Files Suit Against Trio of COVID-19 Vaccine Makers
- Allen v. Cooper (4th Cir. 2026)
- To Require an Inventor ID, or Not to Require an Inventor ID – That Is the Question
about
Month: October 2007
-
By Kevin E. Noonan — Judge James C. Cacheris, Senior Judge sitting in the U.S. District Court for the Eastern District of Virginia, delivered what is perhaps the most significant ruling in U.S. patent law this year (and this includes the Supreme Court’s KSR Int’l Co. v. Teleflex, Inc. opinion). He granted GlaxoSmithKline’s…
-
By Sherri Oslick — Trick or treat, USPTO. An injunction from Eastern District of Virginia for your goodie bag. Shortly after 12 noon EDT on Halloween day, October 31, Judge James C. Cacheris granted GSK’s motion for preliminary injunction, enjoining the USPTO from implementing its new rules. And yet, throughout the entirety of…
-
By Christopher P. Singer — Nventa Biopharmaceuticals Corporation announced on October 29, 2007 that U.S. Patent 7,262,014, titled "Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins" has been granted by the U.S. Patent and Trademark…
-
Judge James C. Cacheris of the Eastern District of Virginia has issued his Order, Memorandum and Opinion, and Minute entry for proceedings following today’s hearing in the consolidated cases of SmithKline Beecham Corp. v. Dudas and Tafas v. Dudas. Patent Docs will provide additional coverage of the Court’s Order and Opinion later today.
-
By Kevin E. Noonan — As reported earlier today on the PLI Patent Blog, Senator Charles Schumer (D-NY) last Thursday sent a letter to U.S. Patent and Trademark Office Director Jon Dudas (at right), asking the Director to delay implementation of the new continuation and claims rules (see 72 Fed. Reg. 46716). In…
-
By Christopher P. Singer — Back in September, the U.S. Government Accountability Office (GAO) published a report to the Ranking Member of the House Committee on Oversight and Government Reform detailing how current U.S. Patent and Trademark Office hiring efforts are likely insufficient to reduce the current application backlog. The report identifies that…
-
By Sherri Oslick — In a nonprecedential opinion, the CAFC has affirmed the decision of the Board of Patent Appeals and Interferences dismissing the interference at issue after finding the appellant’s claims invalid for failure to comply with the written description requirement of 35 U.S.C. § 112, first paragraph. In 1995, Adang and…
-
By Robert Dailey — The Intellectual Property Owners Association (IPO) has finally weighed in on the new Markush rules that were released this August (see 72 Fed. Reg. 44992 (Aug. 10, 2007); "Patent Office Proposes New Rules for Alternative Claiming"). The comments center on two themes: (1) that the new rules have the…
-
By Kevin E. Noonan — The patent blogging team of John White and Eugene Quinn will be doing their part to keep the rest of us informed about the progress of the temporary restraining order/preliminary injunction hearing to be held on Wednesday in GlaxoSmithKline’s lawsuit against Jon Dudas and the U.S. Patent and…
-
By Donald Zuhn — Ryogen LLC announced today that it had been granted U.S. Patent No. 7,273,718. The ‘718 patent, which relates to an isolated genomic polynucleotide fragment that encodes human soluble (cytosolic) aminopeptidase P, appears to be the Suffern, New York-based genomics company’s second U.S. patent. According to Ryogen’s website, the company,…
Patent Docs 